{"id":"W4410816202","doi":"10.1200/jco.2025.43.16_suppl.tps4214","title":"PROSPERO: A phase 3 randomized, placebo (Pbo)-controlled study of amezalpat (TPST-1120), a peroxisome proliferator-activated receptor a (PPARα) inhibitor, in combination with atezolizumab + bevacizumab (AB) for patients (pts) with unresectable or metastatic hepatocellular carcinoma (mHCC) not previously treated with systemic therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Atezolizumab; Placebo; Bevacizumab; Internal medicine; Peroxisome proliferator-activated receptor; Pharmacology; Receptor; Oncology; Urology; Cancer; Chemotherapy; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003581801,0.002207187,0.003301269,0.0005820265,0.0007954885,0.001673752,0.001033358,0.003050688,0.01026897],"category_scores_gemma":[0.002895244,0.0008878646,0.003462918,0.0006407233,0.001321872,0.001626694,0.0006252918,0.003489587,0.001832463],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009806855,"about_ca_system_score_gemma":0.00274033,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001623706,"about_ca_topic_score_gemma":0.004839295,"domain_scores_codex":[0.9988092,0.0007132586,0.00008047774,0.0001963081,0.00008536685,0.0001153541],"domain_scores_gemma":[0.9989725,0.0002246458,0.0003488406,0.0000821259,0.0001062278,0.0002656954],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.960094,0.004567209,0.0006470879,0.005792738,0.002025988,0.00008337018,0.00008613795,0.0002102432,0.004476951,0.0003389064,0.003882851,0.01779457],"study_design_scores_gemma":[0.9745287,0.02047495,0.0009300471,0.000142669,0.0006447341,0.00005060355,0.00002027097,0.00007560969,0.0002282207,0.000175229,0.002715404,0.00001358636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7539537,0.09224898,0.005362401,0.006878538,0.005525058,0.09105922,0.02413691,0.001067292,0.01976785],"genre_scores_gemma":[0.8159809,0.0342401,0.01625869,0.0137525,0.002183679,0.08365278,0.01342947,0.0002124592,0.02028936],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01026897,"threshold_uncertainty_score":0.03435308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03455723363610489,"score_gpt":0.3538965569478587,"score_spread":0.3193393233117538,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}